Elan Sues Over Biogen Objection To $1B J&J Deal

Law360, New York (August 06, 2009, 5:39 PM ET) -- Elan Corp. PLC went on the offensive Thursday against Biogen Idec Inc., its partner in developing the multiple sclerosis treatment Tysabri, to secure a court order that a $1 billion acquisition deal with a Johnson & Johnson affiliate does not violate its collaboration agreement with Biogen Idec.

Elan Pharma International Ltd. filed suit in the U.S. District Court for the Southern District of New York, seeking a declaration that its parent company can go ahead with the transaction, despite a letter Biogen Idec sent to the...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required